Efficacy of the Systemic Immune Inflammation Index in Malignant and Benign Parotid Neoplasms.
| Autor: | Sahin A; Otorhinolaryngology, Ataturk University, Faculty of Medicine, Erzurum, TUR., Kars A; Otorhinolaryngology, Erzincan Binali Yildirim University, Faculty of Medicine, Erzincan, TUR., Kilic K; Otorhinolaryngology, Ataturk University, Faculty of Medicine, Erzurum, TUR., Ucar HB; Otorhinolaryngology, Ataturk University, Faculty of Medicine, Erzurum, TUR., Sakat MS; Otorhinolaryngology, Ataturk University, Faculty of Medicine, Erzurum, TUR. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2022 Nov 25; Vol. 14 (11), pp. e31878. Date of Electronic Publication: 2022 Nov 25 (Print Publication: 2022). |
| DOI: | 10.7759/cureus.31878 |
| Abstrakt: | Objective Several studies have looked at systemic immune-inflammation index (SII) (neutrophil x platelet x lymphocyte) values, which have been shown to be useful in determining tumor aggressivity and prognosis, as well as predicting recurrence risk, particularly in cancer cases. The purpose of the current study was to determine SII values in patients with parotid masses and investigate their utility in distinguishing between malignant and benign parotid tumors. Methods This retrospective study included 237 adult patients-112 women and 125 men-who were followed up on and treated for parotid mass between 2015 and 2021. The SII values determined were compared between the groups. Results The difference between the two groups was statistically significant (p = 0.001). In addition, SII values were higher in malignant tumors with perineural and lymphovascular invasion compared to other malignant tumors, although the difference was not statistically significant. Conclusions Although SII values yielded significant results in differentiating malignant from benign parotid tumors, since no significant cut-off value was determined, we do not think that they represent an effective marker capable of being used to distinguish between these tumors in clinical practice. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Sahin et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|